R&D channel feed – Endpoints News

R&D channel feed

Can CBD temper Parkinson's-related psychosis? UK researchers will look for answers in PhII study

6 years ago

Gilead vet Alessandro Riva steers Glenmark's biotech spinoff on independent course

6 years ago

That big neurosciences R&D group Eli Lilly built is being dismantled, with layoffs and parts shipped home

6 years ago

Surprising Wall Street, Reata unveils positive pivotal data on Friedreich’s ataxia drug

6 years ago

US mulls tariffs on Swiss drug exports, weighing on Novartis and Roche – report

6 years ago

In-house FDA review flags a suspicious imbalance in deaths as Shionogi hunts an OK for antibiotic

6 years ago

A predator's world? Top analyst sees the 'haves' and the 'haven'ts' diverge as biotech bubbles form — and collapse

6 years ago

Cell therapy startup raises $16 million to fund its quest for the Holy Grail in regenerative medicine

6 years ago

Pelosi drug pricing bill promises savings, but could gag R&D — CBO analysis

6 years ago

Pfizer takes aim at a flagship franchise at Sanofi and Regeneron — and scores a few direct hits

6 years ago

First place finish: Eli Lilly just moved to franchise leader with their second migraine drug OK in 1 year

6 years ago

Court green-lights Clovis case after detailing evidence the board ‘ignored red flags’ on false safety and efficacy data

6 years ago

Long term data echo safety profile of Gilead, Galapagos' potential blockbuster JAK inhibitor

6 years ago

Researchers find 15% of trials could be replicated using real world data

6 years ago

Ex-AbbVie partner Principia posts encouraging PhII results for its BTK-inhibitor

6 years ago

J&J hands off non-opioid painkiller to an upstart in the race for next-gen analgesics

6 years ago

Bill Gates backs Ginkgo Bioworks' $350M raise to fuel the buzzy synthetic biology 'revolution'

6 years ago

Neglected on Wall Street, little Stealth Bio finds an affluent chum with $30M in cash and high hopes for their PhIII drug

6 years ago

Shionogi celebrates antibiotic win in pneumonia just ahead of its date with FDA regulators

6 years ago

Partner Bayer pushes Ionis' antithrombotic drug into mid-stage development

6 years ago

The new top 20 pharma list: Takeda jumps on, Biogen pushed out — and more big changes are on the way

6 years ago

A new player is taking the field in a push for a hemophilia A gene therapy, and it’s a big one

6 years ago

Rare disease clinical trials: FDA awards $15M in grants

6 years ago

Stuck with a PhIII gene therapy failure at 96 weeks, GenSight prefers the upbeat assessment

6 years ago

First page Previous page 228 229 230231232 233 234 Next page Last page